Baxter’s REVACLEAR Dialyzer May Offer New Benefits
A new study of 37,500 HD patient records found that use of a REVACLEAR high flux dialyzer was linked to the need for 100 to 600 fewer units of ESA per treatment than matched patients who used an Optiflux® 160 or 180 dialyzer. Researchers also noted a trend toward lower IV iron doses with the Revaclear—while keeping the same HD dose and hemoglobin level.
Read the full article » | Posted 08-09-2016
Related Articles
- Outset Gets FDA Green Light Posted 08-11-2022
- Outset Halts Tablo Sales for Home Use Pending FDA Review of New Features Posted 07-13-2022
- Baxter Showcases Kidney Care Products Posted 06-10-2022
- DaVita and Medtronic to Launch New Kidney Tech Company Posted 06-10-2022